Related Experiment Video
Updated: May 11, 2026
11:13
Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
PI3K pathway in gynecologic malignancies.
Helga B Salvesen1, Henrica Maria Werner, Camilla Krakstad
1From the Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway; Institute of Clinical Sciences, University of Bergen, Bergen, Norway.
Summary
Alterations in the PI3K pathway are common in gynecologic cancers like endometrial and ovarian types. Further research is needed to understand how these genetic changes impact tumor behavior and guide PI3K inhibitor therapies.
Area of Science:
- Oncology
- Molecular Biology
- Gynecologic Oncology
Background:
- Phosphatidylinositol 3-kinase (PI3K) signaling pathway alterations are frequently observed in various gynecologic malignancies.
- The specific PI3K pathway alterations differ based on cancer type, histologic subtype, and clinical presentation.
Purpose of the Study:
- To review the landscape of PI3K pathway alterations in gynecologic cancers.
- To explore the clinical relevance of these alterations and their potential as predictive biomarkers for PI3K inhibitor therapy.
Main Methods:
- Literature review of studies investigating PI3K pathway member alterations (mutations, amplifications, deletions) in endometrial, ovarian, and cervical cancers.
- Analysis of immunohistochemical studies assessing protein expression as surrogate markers for PI3K pathway activation.
Main Results:
- PIK3CA mutations and amplifications are prevalent in endometrial, ovarian, and cervical cancers.
- PTEN mutations and deletions are common in endometrial cancers.
- Current biomarkers for PI3K activity in clinical samples are not well-established.
Conclusions:
- The clinical significance of PI3K pathway member alterations and their impact on tumor behavior requires further investigation.
- Establishing predictive biomarkers for PI3K inhibitor response is crucial for improving patient outcomes in gynecologic malignancies.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:11IP3/DAG Signaling Pathway
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...